NCT02536794
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: Patients with unstable progressing brain metastases or leptomeningeal disease- see trial for details
https://ClinicalTrials.gov/show/NCT02536794